Methanol, an alcohol that is potentially dangerous, is being traced to many products.

Fresh Express has issued a precautionary recall of products containing iceberg lettuce, red cabbage, and carrots that may be linked to a Cyclospora outbreak in the Midwest, the Food and Drug Administration announced. As of July 9, 509 people have gotten Cyclospora infections after consuming bagged salad

HERTFORDSHIRE, EnglandandPITTSBURGH andTOKYO, July9, 2020 /PRNewswire/ --Mylan N.V.(NASDAQ:MYL) and Fujifilm Kyowa Kirin Biologics Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Hulio®(adalimumab-fkjp), a biosimilar to AbbVie's Humira®(adalimumab), for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis (4 years and older), psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis, in both prefilled syringe and auto-injector presentations.Mylan President Rajiv Malik commented: "We are very pleased with FDA's approval of Hulio, a biosimilar to the world's top selling drug Humira, which will help bring another treatment option to U.S. patients living with chronic inflammatory conditions. This approval represents yet another date-certain launch opportunity and demonstration of our commitment to expand patients' access to medicine thanks to the power of our global platform, including our global reach and scale, our continued demonstration of scientific excellence, and the benefits of strategic partnerships, such as the one we are proud to have with Fujifilm Kyowa Kirin Biologics. With one of the industry's largest and most diverse global biosimilars franchises, Mylan is committed to improving patient access to this and other critically important biologic medicines as well as providing more affordable treatment options for patients worldwide.""The FDA approval of Hulio marks a significant milestone for both Fujifilm Kyowa Kirin Biologics and Mylan, increasing access to affordable treatment forU.S. patientswith inflammatory conditions." saidAtsushi Matsumoto, Fujifilm Kyowa Kirin Biologics President and CEO. "In cooperation with Mylan, we continue to make alleffortsto deliverthis high quality and affordable biosimilar throughout the world."